CYCA has multiple cutting-edge solutions for the rising security crisis needs that have emerged today.

These include:

Technology Solutions Provider Addressing Various Industries for Integration, Streaming, Transfer, and Storage of Video and Audio Data.

Launched Crisis Alert and Response Emergency System Mobile Application to Revolutionize School Safety.

Instant SOS Alert Automatically Triggers a Video Call That is Shared with All Emergency Responders Responsible for Protecting a School.

Initiative for Florida Law Enforcement Agencies Generates Overwhelming Response Amid New Drone Regulation Changes.

Strong Success for Groundbreaking AI-Enhanced Marketing Campaign in Florida.

Multiple Florida Police Departments and Sheriff's Offices chose CYCA CyttaCOMMS as their Drone Streaming Solution.

Source:
https://einpresswire.com/article/718765251/law-enforcement-adopts-cytta-corp-versatile-drone-tech-cyttacares-addresses-school-safety-crisis-cytta-otcqb-cyca

$GTVH News: Golden Triangle Ventures Provides Full Update on Its Flagship Destino Ranch Project

LAS VEGAS, June 20, 2024 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC PINK: GTVH) (“GTV” or the “Company”) is pleased to announce an update on its premier project, Destino Ranch, which is being developed by the Company’s Entertainment Division through its wholly owned subsidiary, Lavish Entertainment (or “Lavish”). Destino Ranch is a bold and visionary project led by Lavish, set to transform luxury entertainment and hospitality. Located in the stunning Mojave Desert, Destino Ranch is designed to provide a unique combination of world-class entertainment, opulent accommodations and immersive experiences.

Over the past six months, significant progress has been made in developing Destino Ranch. Upon taking possession of the nearly 70-acre ranch and its overall infrastructure, which included 643 trees, only 35% of the irrigation system was properly functional while most watering was done using a water truck. Today, 98% of the irrigation system is now operational following a massive overhaul. Key improvements include replacing and updating 95% of all control valves, re-energizing all existing waterlines, and making numerous major system enhancements. The extensive cleanup efforts have also included the repair of perimeter fencing, reinstallation of gates, and opening of roadways around the project.

Improvements in the water supply system include updating lines and control valves to the storage system and revamping the well system. Tree care has been a primary focus, involving pruning and trimming for health benefits and ongoing fruit production. All dead trees have been removed, and new planting is planned to further enhance the project by adding additional fruit trees and various ornamental shade trees. Plans include adding numerous colorful trees and plants to create a park-like atmosphere, improving the environment and enhancing the overall aesthetic appeal of Destino Ranch.

Management is diligently collaborating with city planners and council members to secure the necessary permits and approvals for the Destino Ranch project. This comprehensive effort encompasses the creation of detailed development and engineering plans, alongside strategizing the acquisition of additional property essential for the project’s completion. The Company is actively engaged in future concept planning to ensure long-term success. As part of this strategic initiative, the Company is also focused on assembling a stellar board of team members and directors, whose expertise will propel the project forward. Concurrently, the Company is identifying key vendors and determining specific site placements, developing a precise site map to guide the development of Destino Ranch.

Golden Triangle Ventures has garnered overwhelming support for the Destino Ranch project and is actively exploring several non-dilutive funding options to advance its development. With a dedicated team working tirelessly on-site, the Company is diligently preparing for a significant development, poised to launch events and establish Destino Ranch as a premier entertainment destination. To bolster these efforts, Lavish Entertainment has strategically retained Cayenne Consulting, leveraging its expertise in business planning, feasibility studies, revenue modeling, and strategic advisory services. Cayenne Consulting’s tailored suite of services aligns perfectly with Lavish’s holistic approach to project development and management. Currently, finalization of the investor packet from Cayenne Consulting under the guidance of Marco Moreno, the appointed president and chief operations officer of Lavish Entertainment, marks the last crucial step towards substantiating the complete project financing.

Destino Ranch Website: http://www.DestinoRanch.com

Destino Ranch Instagram: @DestinoRanch

Destino Ranch Twitter: @DestinoRanch

About Lavish Entertainment, Inc.

Lavish Entertainment, Inc. is a wholly owned subsidiary of Golden Triangle Ventures operating under its Entertainment Division. Currently conducting its business out of Las Vegas, Nevada, the Company was established in 2017 with a vision of becoming nationally recognized in concert production. The Company currently has more than 30,000 national followers and nearly 100 team members who have helped Lavish successfully organize some of the most exciting electronic dance music concerts in Las Vegas. Lavish Entertainment strives to produce high quality and professional events that provide an immersive experience through state-of-the-art production and sound implementation.

Lavish is currently developing a flagship entertainment complex called Destino Ranch, which intends to become an ideal outdoor music and festival venue, immersive art installation, tourist attraction and world-renowned destination center. The Company recently secured a purchase agreement to acquire nearly 70 acres of prime and improved land for its Destino Ranch project, which is strategically located in Arizona. The property has upgrades that represent a substantial investment totaling nearly $6 million, which has turned this once-vacant land into a beautiful oasis that provides the initial infrastructure needed to begin the development of Destino Ranch.

Lavish Entertainment’s business model encompasses the following key foundational elements: logistics, staffing, equipment, and production. These pillars were meticulously identified and organized to complement its Destino Ranch project, along with ensuring seamless operations across all facets of the Company. To enhance its bandwidth and expand service offerings, the Company intends to develop and acquire operations in each of the four key areas.

Lavish Entertainment recently appointed Marco Antonio Moreno as its new president and chief operations officer. Moreno is the founder, senior designer and lead project manager for ABI Create, L.L.C. (“ABI”). Formed in 2015, and based out of Phoenix, Arizona, ABI is a complete-service event management and production firm offering:

-Event Organization, Management, Production and Logistics
-Site Planning and Permitting
-Construction and Contracting
-Custom Design and Fabrication
-And More

ABI Create has successfully implemented its corporate vision of delivering high-fidelity production to large-scale installations that span major music festivals, major sporting events and notable conventions across the United States. Notable collaborative work samples include projects produced for:

-NFL Super Bowl
-San Diego & New York Comic-Con
-EDC & Camp EDC and Other Insomniac Events
-Bonnaroo Music Festival
-The Waste Management Phoenix Open and Arnold Palmer Invitational
-Burning Man

More information on Moreno, along with his collaborators, partners and team, can be found at http://www.abicreate.com or @marco.a.moreno

ABI was a crucial team member in the production of Lavish Entertainment’s Playa Playground New Year’s event (“Playa”). Held on Dec. 31, 2021, Playa was an auspicious and grand-scale Burning-Man-style music festival staged in downtown Las Vegas that redefined the level of event that Lavish can provide. Due to the role ABI played in the execution of Playa, the CEO of Golden Triangle Ventures, Steffan Dalsgaard, handpicked Moreno to lead the new vision of Lavish and contribute to the Company’s overarching business goal of becoming an industry leading, innovative and at-the-forefront music and arts entertainment production Company.

About Golden Triangle Ventures, Inc.

Golden Triangle Ventures, Inc. or “GTV” is a multifaceted consulting Company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors, along with others that provide synergistic value to these three core divisions. The Company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The Company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors in which this Company aims to do business. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the Company. An amazing team of professionals support each division and continue to help the Company grow daily. Being a publicly traded Company gives the ability to provide the support needed to help each subsidiary grow into the businesses management believes they can and will become.

Golden Triangle Ventures’ business model is supported by the drive for vertical integration to cut costs and maximize margins. Management strives to acquire entities and assets that they fully understand, which maintain the prospect for long term exponential growth. The mission is to provide the necessary resources for each subsidiary to generate profit, and then allow them to leverage each other and maximize economic impact. In addition, GTV provides a professional corporate representation service to different companies in these sectors while consulting on a variety of different business development objectives.

The backbone of this business is truly a team of professional advisors looking to help companies with a multitude of corporate objectives. With an extensive Rolodex of relationships, management can help with a dynamic range of project obstacles while maintaining a quality service for each client the Company represents. No matter what the needs are, the team involved can help facilitate many different transactions successfully for all parties involved. The network of relationships expands to industry experts who can assist with project management, product sourcing, industrial agriculture project implementation and so much more. Golden Triangle Ventures develops strategies and detailed plans that are custom-tailored to each corporate need and objective in all areas of business.

The GTV business model is focused on the following core group of interests:

Acquisitions / Assets / Holdings - The Company currently owns a unique portfolio of companies that are all being developed and supported by GTV, each holding a common goal of making a positive impact in the industry in which they operate.

Services - Services are deployed through Golden Triangle Ventures to assist all the unique opportunities within its operation. The Company also offers its services to select opportunities that could develop synergistic value within the relationship between both companies through the result of its efforts.

Investments - Management identifies high-value opportunities and provides capital investments in several companies and projects being developed. Each investment is complemented by a hands-on approach of helping to develop the overall direction and strategic plan for each opportunity.

www.GoldenTriangleInc.com

FORWARD-LOOKING INFORMATION

Certain information set forth in this press release contains "forward-looking information," including "future-oriented financial information" and "financial outlook," under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to give potential investors the opportunity to understand management's beliefs and opinions in respect to the future so they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material nonpublic information. In this regard, investors and others should note that we announce material financial information on our Company website, http://www.GoldenTriangleInc.com, in addition to SEC filings, press releases, public conference calls and webcasts. We also use social media to communicate with the public about our Company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, in light of the SEC's guidance, we encourage investors, the media and others interested in our Company to review the information we post on the following U.S. social media channels:

Twitter: http://www.twitter.com/GTV_Inc

CONTACT INFORMATION

Golden Triangle Ventures, Inc.
info@GoldenTriangleInc.com

Corporate Communications
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

$CYCA: CyttaCARES - Revolutionizing Safety and Security in Educational Institutions

$CYCA: CyttaCARES - Revolutionizing Safety and Security in Educational Institutions

$IVDN is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year. This has been pre-announced in the last two IVDN news releases:

Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html

Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html

With IVDN now on track for a record sales year in 2024, this key investment principle could not be more appropriate:

The Power of Patience: Warren Buffett’s Advice on Investing in the Stock Market
Quote:
The stock market is a device for transferring money from the impatient to the patient.

Analysis of the quote

The quote “The stock market is a device for transferring money from the impatient to the patient” was written by none other than Warren Buffett, widely regarded as one of the greatest investors of all time. Buffett is the chairman and CEO of Berkshire Hathaway, a multinational conglomerate holding company with a diverse portfolio of businesses in insurance, energy, railroads, manufacturing, and retail. As of the 2nd of March 2023, the oracle of Omaha has amassed a net worth of more than $100 billion over the course of his career, owing largely to his astute stock market investments. Buffett’s investment philosophy revolves around identifying high-quality companies with strong competitive advantages and investing in them for the long term, often with a holding period of 10 years or even more. A strategy also known as value investing.
Source:
https://www.simtrade.fr/blog_simtrade/the-power-of-patience-advice-from-warren-buffett/#:~:text=The%20quote%20%E2%80%9CThe%20stock%20market,greatest%20investors%20of%20all%20time.

$CCTG News: CCSC Technology International Holdings Limited Enters into International Purchase Agreement with SHI / LIGHTCARE-SOLUTIONS ApS

Hong Kong, June 20, 2024 (GLOBE NEWSWIRE) -- CCSC Technology International Holdings Limited (the “Company” or “CCSC”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced that it has entered into an international purchase agreement (the “Agreement”) with SHI / LIGHTCARE-SOLUTIONS ApS (“SHI”), a Danish company that primarily engages in the design and supply of healthcare lighting products.

Pursuant to the Agreement, CCSC will manufacture and supply healthcare lighting products based on the designs provided by SHI to customers in the Asia Pacific region. Under this Agreement, the parties estimate that the annual purchasing amount will start at €0.50 million (approximately US$0.54 million) in 2025 and increase to €3.50 million (approximately US$3.76 million) in 2030.

Mr. Kung Lok Chiu, Chief Executive Officer and Director of the Company, commented, “We are thrilled to partner with SHI to expand our healthcare lighting business in the Asia Pacific market. This partnership aligns with our strategic goal of diversifying our product portfolio and expanding our presence in the healthcare sector. Through our collaboration with SHI, we are poised to deliver innovative and effective lighting solutions that meet the needs of customers in the healthcare industry. We believe this collaboration will drive growth for both companies in the foreseeable future.”

About CCSC Technology International Holdings Limited

CCSC Technology International Holdings Limited, is a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products. The Company specializes in customized interconnect products, including connectors, cables and wire harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. The Company produces both OEM (“original equipment manufacturer”) and ODM (“original design manufacture”) interconnect products for manufacturing companies that produce end products, as well as electronic manufacturing services (“EMS”) companies that procure and assemble products on behalf of such manufacturing companies. The Company has a diversified global customer base located in more than 25 countries throughout Asia, Europe and the Americas. For more information, please visit the Company’s website: http://ir.ccsc-interconnect.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

CCSC Technology International Holdings Limited
Investor Relations Department
Email: ir@ccsc-interconnect.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

https://www.globenewswire.com/newsroom/ti?nf=OTE1NTg4NSM2MzIzMTcxIzUwMDEyMTQ3OQ==
https://ml.globenewswire.com/media/MGFmNWE3ZTUtNmNlNS00MzUwLTg2ZTAtOTNhYjhkNDM3NWE1LTUwMDEyMTQ3OQ==/tiny/CCSC-Technology-International-.png

Source: CCSC Technology International Holdings Limited

$CCTG News: CCSC Technology International Holdings Limited Enters into International Purchase Agreement with SHI / LIGHTCARE-SOLUTIONS ApS

Hong Kong, June 20, 2024 (GLOBE NEWSWIRE) -- CCSC Technology International Holdings Limited (the “Company” or “CCSC”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced that it has entered into an international purchase agreement (the “Agreement”) with SHI / LIGHTCARE-SOLUTIONS ApS (“SHI”), a Danish company that primarily engages in the design and supply of healthcare lighting products.

Pursuant to the Agreement, CCSC will manufacture and supply healthcare lighting products based on the designs provided by SHI to customers in the Asia Pacific region. Under this Agreement, the parties estimate that the annual purchasing amount will start at €0.50 million (approximately US$0.54 million) in 2025 and increase to €3.50 million (approximately US$3.76 million) in 2030.

Mr. Kung Lok Chiu, Chief Executive Officer and Director of the Company, commented, “We are thrilled to partner with SHI to expand our healthcare lighting business in the Asia Pacific market. This partnership aligns with our strategic goal of diversifying our product portfolio and expanding our presence in the healthcare sector. Through our collaboration with SHI, we are poised to deliver innovative and effective lighting solutions that meet the needs of customers in the healthcare industry. We believe this collaboration will drive growth for both companies in the foreseeable future.”

About CCSC Technology International Holdings Limited

CCSC Technology International Holdings Limited, is a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products. The Company specializes in customized interconnect products, including connectors, cables and wire harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. The Company produces both OEM (“original equipment manufacturer”) and ODM (“original design manufacture”) interconnect products for manufacturing companies that produce end products, as well as electronic manufacturing services (“EMS”) companies that procure and assemble products on behalf of such manufacturing companies. The Company has a diversified global customer base located in more than 25 countries throughout Asia, Europe and the Americas. For more information, please visit the Company’s website: http://ir.ccsc-interconnect.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

CCSC Technology International Holdings Limited
Investor Relations Department
Email: ir@ccsc-interconnect.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

https://www.globenewswire.com/newsroom/ti?nf=OTE1NTg4NSM2MzIzMTcxIzUwMDEyMTQ3OQ==
https://ml.globenewswire.com/media/MGFmNWE3ZTUtNmNlNS00MzUwLTg2ZTAtOTNhYjhkNDM3NWE1LTUwMDEyMTQ3OQ==/tiny/CCSC-Technology-International-.png

Source: CCSC Technology International Holdings Limited

$RENB News: Renovaro, Inc. Announces $10 million in Equity Committed

LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage.

“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO. “We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars.”

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.

$RENB News: Renovaro, Inc. Announces $10 million in Equity Committed

LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage.

“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO. “We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars.”

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.

$CATV: Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector

MIAMI, May 15, 2024 /PRNewswire/ -- 4Cable TV International, Inc. soon to be known as Category V Biotech, Inc. (OTC: CATV) announced today the execution of a Letter of Intent (LOI) to acquire Genetic Networks, LLC (https://geneticnetworks.com/), a leader in applied molecular biology and drug development. Effective May 15, 2024, the LOI signifies Category V Biotech's acquisition of 100% equity interests in Genetic Networks, marking the company's entry into the biotechnology sector of the Cannabis industry and solidifying its position as a fully integrated global leader in this space.

Genetic Networks brings a proprietary platform known as GeneScape™, which facilitates the rapid and unbiased discovery of optimal drug compounds through whole-genome analysis. By integrating functional assays of drug activity and human gene variants, GeneScape™ can identify the most promising targets and compounds for specific diseases, expediting development timelines and reducing costs. This acquisition enables Category V Biotech to expand into the biotech aspect of the Cannabis industry, leveraging Genetic Networks' expertise in accelerating compound discovery and development for pre-clinical and clinical testing.

"We are excited to welcome Genetic Networks into the Category V Biotech family," stated Michael Feldenkrais, CEO of Category V Biotech. "Their state-of-the-art platform and extensive knowledge will be instrumental as we strive to unlock the full potential of Cannabis-based therapeutics. Together, we anticipate bringing novel treatments to patients faster than ever before as regulated FDA products under the new regulatory environment of the United States."

Under the agreement's terms, Category V Biotech will acquire 100% of Genetic Networks. The transaction is expected to conclude in the second quarter of 2024, pending customary closing conditions.

Dr. Gennaro D'Urso, co-founder of Genetic Networks, echoed this enthusiasm, stating, "Category V Biotech shares our dedication to leveraging genetics to revolutionize drug development. By joining forces, we envisage broadening the reach and impact of our platform, ultimately delivering superior medicines to patients in need."

Following the acquisition, Genetic Networks will operate as a wholly owned subsidiary of Category V Biotech, retaining its existing management team and facilities. Category V Biotech plans to leverage Genetic Networks' capabilities across its global Cannabis operations, including cultivation, biotech research, and retail.

This transaction is the culmination of years of discussions, awaiting the right moment for research and development in the United States to create pharmaceutical-grade products using Cannabis. With the recent announcement of the rescheduling of Cannabis from Controlled Substance I to Controlled Substance III, reflecting a change in U.S. policies, the long-awaited strategy can now come to fruition. This shift paves the way for Category V Biotech and Genetic Networks to capitalize on emerging opportunities in the Cannabis industry, driving innovation and advancing therapeutic solutions for patients.

Category V Biotech remains actively engaged in pursuing additional acquisitions in the Cannabis industry as part of its growth strategy, with further transactions expected to be announced in the coming months.

About Genetic Networks, LLC

Genetic Networks, LLC, established in 2015, has been at the forefront of serving three of the top ten bio-pharmaceutical companies with its GeneScape™ technology. GeneScape™ expedites drug asset development through applied molecular biology, offering a multidimensional map of diseases and drugs that integrates genome-wide functional assays of drug activity (H-Tech) and human genes and gene variants (Y-Tech) using proprietary analytics. Genetic Networks' GeneScape™ platform accelerates the discovery and development of optimal candidate compounds for pre-clinical and clinical testing, identifying the optimal intersection between targets and compounds in specific disease spaces through whole-genome genetic perturbation and analysis.

About Category V Biotech, LLC, Inc.

Category V Biotech, LLC, Inc. (OTC: CATV) aims to establish and operate a fully integrated global Cannabis company, encompassing biotech research, cultivation, manufacturing, and retail. Through strategic acquisitions and organic growth, the company strives to emerge as the world's leading provider of pharmaceutical Cannabis- based products and therapies.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements regarding Category V Biotech, LLC's business, which are not historical facts but are based on the company's current beliefs, expectations, and assumptions about its future business, plans, strategies, projections, anticipated events, and trends. Such forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are beyond the company's control. Actual results and financial conditions may differ materially from those indicated in the forward- looking statements due to various factors. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, made from time to time, except as required by law.

SOURCE: 4Cable TV International, Inc a/k/a Category V Biotech, LLC, Inc. (OTC: CATV)

Contact: info@4cabletvint.com, +1 3055289614

Cision View original content:https://www.prnewswire.com/news-releases/category-v-biotech-inc-announces-letter-of-intent-to-acquire-genetic-networks-expanding-into-biotechnology-sector-302146392.html

SOURCE 4Cable TV International, Inc.

$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors

Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology

Retired at a rank that is the civilian equivalent of a senior flag officer from the United States Navy

RADNOR, Pa., June 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has added Dr. Dennis McBride to its Board of Directors. Dr. McBride brings deep experience in Neuroscience, Medical and Information Technology and digital therapeutics to the Company.

"I am delighted to welcome Dennis to the Board of NRx. His unique background in both Neuroscience and Medical Technology will be an important asset to the company as we seek to develop more advanced treatments for patients," said Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx. "I have worked with Dennis previously on a highly successful digital therapeutic and know the quality he brings to our company."

"I am proud to join the Board of NRx at such an exciting time for the company – the opportunities have never been greater in Neuroscience to advance and improve novel therapies," commented Dr. McBride. "I look forward to using my experience to help advance its strategy and further the development of NRx's impressive pipeline of CNS products and leading its initiative in digital therapeutics."

Dr. Dennis McBride has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development both within the federal government and in the private sector, three of which are now multi-billion-dollar enterprises. He has formative experience in CNS-focused digital therapeutics, having participated with NRx founders in developing now military-proven digital therapeutic technology for reduction of stress and depression. He was instrumental to the founding of InQTel and other private sector-focused initiatives.

Dr. McBride dedicated his Navy career to Aerospace Medicine and ergonomics, during which he served in leadership roles at six nationally-prominent laboratories, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated Navy Captain, he assumed leadership of the Potomac Institute for Policy Studies, where he continues to serve as President Emeritus. He then joined the National Defense University as a Professor to lead the Center for Technology and National Security Policy, completing his term as a Senior Executive-4 (Civilian equivalent to Vice Admiral). Most recently, he served a tour of duty in the Office of the Secretary of Defense. Dr. McBride has served as an adviser to Cabinet Secretaries, US Congressional Committees, and to corporate C-Suite executives. His educational background includes the University of Georgia, Naval Aerospace Medical Institute, the University of Southern California, the London School of Economics, and Harvard Business School, earning a Ph.D. in experimental psychology and four master's degrees.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

https://c212.net/c/img/favicon.png?sn=CL42013&sd=2024-06-18 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-appoints-neuroscience-information-technology-and-medical-technology-veteran-to-its-board-of-directors-302175147.html

SOURCE NRx Pharmaceuticals, Inc.

$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors

Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology

Retired at a rank that is the civilian equivalent of a senior flag officer from the United States Navy

RADNOR, Pa., June 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has added Dr. Dennis McBride to its Board of Directors. Dr. McBride brings deep experience in Neuroscience, Medical and Information Technology and digital therapeutics to the Company.

"I am delighted to welcome Dennis to the Board of NRx. His unique background in both Neuroscience and Medical Technology will be an important asset to the company as we seek to develop more advanced treatments for patients," said Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx. "I have worked with Dennis previously on a highly successful digital therapeutic and know the quality he brings to our company."

"I am proud to join the Board of NRx at such an exciting time for the company – the opportunities have never been greater in Neuroscience to advance and improve novel therapies," commented Dr. McBride. "I look forward to using my experience to help advance its strategy and further the development of NRx's impressive pipeline of CNS products and leading its initiative in digital therapeutics."

Dr. Dennis McBride has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development both within the federal government and in the private sector, three of which are now multi-billion-dollar enterprises. He has formative experience in CNS-focused digital therapeutics, having participated with NRx founders in developing now military-proven digital therapeutic technology for reduction of stress and depression. He was instrumental to the founding of InQTel and other private sector-focused initiatives.

Dr. McBride dedicated his Navy career to Aerospace Medicine and ergonomics, during which he served in leadership roles at six nationally-prominent laboratories, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated Navy Captain, he assumed leadership of the Potomac Institute for Policy Studies, where he continues to serve as President Emeritus. He then joined the National Defense University as a Professor to lead the Center for Technology and National Security Policy, completing his term as a Senior Executive-4 (Civilian equivalent to Vice Admiral). Most recently, he served a tour of duty in the Office of the Secretary of Defense. Dr. McBride has served as an adviser to Cabinet Secretaries, US Congressional Committees, and to corporate C-Suite executives. His educational background includes the University of Georgia, Naval Aerospace Medical Institute, the University of Southern California, the London School of Economics, and Harvard Business School, earning a Ph.D. in experimental psychology and four master's degrees.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

https://c212.net/c/img/favicon.png?sn=CL42013&sd=2024-06-18 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-appoints-neuroscience-information-technology-and-medical-technology-veteran-to-its-board-of-directors-302175147.html

SOURCE NRx Pharmaceuticals, Inc.

$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year. This has been pre-announced in the last two IVDN news releases:

Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html

Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html

$CYCA News: CyttaAIR Partners with FIZUAS to Dominate the American Drone Reseller and Advanced Streaming Technology Market

Massive Florida Demand for CyttaCOMMS and Drones Drives Partnership

LAS VEGAS, NV / ACCESSWIRE / June 13, 2024 / Cytta Corp (OTCQB:CYCA), a leading provider of innovative technology solutions for public safety and cybersecurity industries, is excited to announce that CyttaAIR, in an expansion of its longstanding reseller partnership with FIZUAS Unmanned Aircraft Systems, a premier national drone reseller, is now entering the drone reseller market. This strategic joint venture aims to meet the growing demand for American-made drones, particularly from law enforcement agencies transitioning away from foreign drones.

A Strategic Move in Response to Growing Demand

This expanded partnership with FIZUAS comes at a critical time when numerous law enforcement agencies in Florida are seeking guidance on which drone brands and models to purchase. This transition to American-made drones is driven by legislative changes and a heightened focus on data security. Through this joint venture, CyttaAIR will provide these agencies with top-tier, compliant drone options, enhancing their operational capabilities and ensuring adherence to new regulations.

Quote from Mike Elliott, VP of Business Development

"We are thrilled to be partnering with a premiere national drone reseller like FIZUAS," said Mike Elliott, VP of Business Development at Cytta Corp. "The number of law enforcement agencies in Florida asking about which drone brands and models to purchase has skyrocketed. This joint venture allows CyttaAIR to expand into this rapidly growing market, providing our clients with the best in American-made drone technology and our leading CyttaCOMMS secure video streaming solution."

Expanding CyttaAIR's Reach

This collaboration is poised to position CyttaAIR as a dominant player in the drone reseller market. By leveraging FIZUAS's extensive reseller network and expertise, CyttaAIR/FIZUAS will jointly offer a comprehensive range of drones equipped with the secure and collaborative capabilities of CyttaCOMMS. This move underscores Cytta Corp.'s commitment to providing cutting-edge technology solutions that meet the evolving needs of law enforcement and other critical sectors.

About Cytta Corp:

Cytta Corp. is a leading technology solutions provider dedicated to delivering innovative products and services across various industries and revolutionizes the integration, streaming, transfer, and storage of video and audio data. With a focus on safety, security, and efficiency, Cytta Corp strives to develop cutting-edge solutions that address real-world challenges in large markets.

The Company's proprietary CyttaCOMMS incident management system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.

About FIZUAS Unmanned Aircraft Systems

FIZUAS is a leading national drone reseller known for providing high-quality, reliable drone solutions to various industries. Their extensive network and extensive first responder and industry expertise make them a trusted partner for organizations looking to integrate drone technology into their operations.

Contact Information
Investor/Shareholder Contact:
Gary Zwetchkenbaum
PlumTree Consulting, LLC.
gzplumtree@gmail.com
Direct: (516)-455-7662

Cytta Corp.
Toll free #: 1 877 CYTTAUS (298 8287)
Call Local: 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com

Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com

Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708

SOURCE: Cytta Corp.

$CYCA News: CyttaAIR Partners with FIZUAS to Dominate the American Drone Reseller and Advanced Streaming Technology Market

Massive Florida Demand for CyttaCOMMS and Drones Drives Partnership

LAS VEGAS, NV / ACCESSWIRE / June 13, 2024 / Cytta Corp (OTCQB:CYCA), a leading provider of innovative technology solutions for public safety and cybersecurity industries, is excited to announce that CyttaAIR, in an expansion of its longstanding reseller partnership with FIZUAS Unmanned Aircraft Systems, a premier national drone reseller, is now entering the drone reseller market. This strategic joint venture aims to meet the growing demand for American-made drones, particularly from law enforcement agencies transitioning away from foreign drones.

A Strategic Move in Response to Growing Demand

This expanded partnership with FIZUAS comes at a critical time when numerous law enforcement agencies in Florida are seeking guidance on which drone brands and models to purchase. This transition to American-made drones is driven by legislative changes and a heightened focus on data security. Through this joint venture, CyttaAIR will provide these agencies with top-tier, compliant drone options, enhancing their operational capabilities and ensuring adherence to new regulations.

Quote from Mike Elliott, VP of Business Development

"We are thrilled to be partnering with a premiere national drone reseller like FIZUAS," said Mike Elliott, VP of Business Development at Cytta Corp. "The number of law enforcement agencies in Florida asking about which drone brands and models to purchase has skyrocketed. This joint venture allows CyttaAIR to expand into this rapidly growing market, providing our clients with the best in American-made drone technology and our leading CyttaCOMMS secure video streaming solution."

Expanding CyttaAIR's Reach

This collaboration is poised to position CyttaAIR as a dominant player in the drone reseller market. By leveraging FIZUAS's extensive reseller network and expertise, CyttaAIR/FIZUAS will jointly offer a comprehensive range of drones equipped with the secure and collaborative capabilities of CyttaCOMMS. This move underscores Cytta Corp.'s commitment to providing cutting-edge technology solutions that meet the evolving needs of law enforcement and other critical sectors.

About Cytta Corp:

Cytta Corp. is a leading technology solutions provider dedicated to delivering innovative products and services across various industries and revolutionizes the integration, streaming, transfer, and storage of video and audio data. With a focus on safety, security, and efficiency, Cytta Corp strives to develop cutting-edge solutions that address real-world challenges in large markets.

The Company's proprietary CyttaCOMMS incident management system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.

About FIZUAS Unmanned Aircraft Systems

FIZUAS is a leading national drone reseller known for providing high-quality, reliable drone solutions to various industries. Their extensive network and extensive first responder and industry expertise make them a trusted partner for organizations looking to integrate drone technology into their operations.

Contact Information
Investor/Shareholder Contact:
Gary Zwetchkenbaum
PlumTree Consulting, LLC.
gzplumtree@gmail.com
Direct: (516)-455-7662

Cytta Corp.
Toll free #: 1 877 CYTTAUS (298 8287)
Call Local: 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com

Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com

Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708

SOURCE: Cytta Corp.

$SHOT: Wellness And Dietary Supplement Company Safety Shot Reports Bringing World's First Patented Rapid Blood Alcohol Detox Solution To Market - Safety Shot (NASDAQ:SHOT) - Benzinga
Click here:
https://www.benzinga.com/partner/emerging-markets/24/06/39361121/wellness-and-dietary-supplement-company-safety-shot-reports-bringing-worlds-first-patent

$SHOT: Wellness And Dietary Supplement Company Safety Shot Reports Bringing World's First Patented Rapid Blood Alcohol Detox Solution To Market - Safety Shot (NASDAQ:SHOT) - Benzinga
Click here:
https://www.benzinga.com/partner/emerging-markets/24/06/39361121/wellness-and-dietary-supplement-company-safety-shot-reports-bringing-worlds-first-patent

The real facts are that IVDN has strongly rising sales (FY 2024 is already double all of last year), new customers, new distributors, patent protection, little debt, insider buying, a small share structure with a very low float of only 16 million shares out, all legal issues resolved in the company's favor and, of course, the highest performing House Wrap insulation on the market with its unique evacuated cell structure delivering an R-6 value that no competitor can mach.

All of this has come together as a result of IVDN management's diligent work over the past several years and has brought the company to its strongest position ever for 2024 and beyond. Everything is well detailed in the official company news below which is fully accountable to the SEC for truthfulness and accuracy. Anything else posted by anonymous individuals on chat boards is accountable to no one and has no credibility at all.

Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html

Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html

World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640

LIG Assets, Inc. Announces Agreement With Insultex House Wrap
October 30, 2023
https://www.globenewswire.com/en/news-release/2023/10/30/2769422/0/en/LIG-Assets-Inc-Announces-Agreement-With-Insultex-House-Wrap.html

Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html

Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html

Innovative Designs, Inc. Receives $100,000 Direct Private Investment from Board Member Mr. Robert K. Adams
June 5, 2023
https://www.globenewswire.com/news-release/2023/06/05/2682134/0/en/Innovative-Designs-Inc-Receives-100-000-Direct-Private-Investment-from-Board-Member-Mr-Robert-K-Adams.html

Innovative Designs, Inc. Receives Significant New Orders for Its Unmatched Insultex House Wrap from Two Repeat Customers
June 1, 2023
https://www.globenewswire.com/news-release/2023/06/01/2680753/0/en/Innovative-Designs-Inc-Receives-Significant-New-Orders-for-Its-Unmatched-Insultex-House-Wrap-from-Two-Repeat-Customers.html

Innovative Designs Receives Patent for Propriety Process With Low Density Foam
April 20, 2023
https://www.globenewswire.com/news-release/2023/04/20/2651420/0/en/Innovative-Designs-Receives-Patent-for-Propriety-Process-With-Low-Density-Foam.html

$AVRW: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results

New Initiatives Showing Encouraging Results

SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.

Key financial highlights for the fourth quarter included the following:

Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.

Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.

Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.

Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.

Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.

"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.

Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.

Operational Highlights

Other operational highlights during the fourth quarter of 2023 included:

Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/

About Avenir Wellness Solutions, Inc.

Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.

About The Sera Labs, Inc.

Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.

Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.

CONTACTS:

Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com

$AVRW: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results

New Initiatives Showing Encouraging Results

SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.

Key financial highlights for the fourth quarter included the following:

Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.

Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.

Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.

Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.

Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.

"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.

Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.

Operational Highlights

Other operational highlights during the fourth quarter of 2023 included:

Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/

About Avenir Wellness Solutions, Inc.

Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.

About The Sera Labs, Inc.

Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.

Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.

CONTACTS:

Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com

$NRXP Innovative Bipolar Depression Treatment by NRx Pharmaceuticals Featured at ASCP June 2024 Meeting -Healthcare Industry Today
Click here:
https://healthcareindustrytoday.com/article/718753903-innovative-bipolar-depression-treatment-by-nrx-pharmaceuticals-featured-at-ascp-june-2024-meeting-nasdaq-nrxp

$NRXP Innovative Bipolar Depression Treatment by NRx Pharmaceuticals Featured at ASCP June 2024 Meeting -Healthcare Industry Today
Click here:
https://healthcareindustrytoday.com/article/718753903-innovative-bipolar-depression-treatment-by-nrx-pharmaceuticals-featured-at-ascp-june-2024-meeting-nasdaq-nrxp

$CATV: Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector

MIAMI, May 15, 2024 /PRNewswire/ -- 4Cable TV International, Inc. soon to be known as Category V Biotech, Inc. (OTC: CATV) announced today the execution of a Letter of Intent (LOI) to acquire Genetic Networks, LLC (https://geneticnetworks.com/), a leader in applied molecular biology and drug development. Effective May 15, 2024, the LOI signifies Category V Biotech's acquisition of 100% equity interests in Genetic Networks, marking the company's entry into the biotechnology sector of the Cannabis industry and solidifying its position as a fully integrated global leader in this space.

Genetic Networks brings a proprietary platform known as GeneScape™, which facilitates the rapid and unbiased discovery of optimal drug compounds through whole-genome analysis. By integrating functional assays of drug activity and human gene variants, GeneScape™ can identify the most promising targets and compounds for specific diseases, expediting development timelines and reducing costs. This acquisition enables Category V Biotech to expand into the biotech aspect of the Cannabis industry, leveraging Genetic Networks' expertise in accelerating compound discovery and development for pre-clinical and clinical testing.

"We are excited to welcome Genetic Networks into the Category V Biotech family," stated Michael Feldenkrais, CEO of Category V Biotech. "Their state-of-the-art platform and extensive knowledge will be instrumental as we strive to unlock the full potential of Cannabis-based therapeutics. Together, we anticipate bringing novel treatments to patients faster than ever before as regulated FDA products under the new regulatory environment of the United States."

Under the agreement's terms, Category V Biotech will acquire 100% of Genetic Networks. The transaction is expected to conclude in the second quarter of 2024, pending customary closing conditions.

Dr. Gennaro D'Urso, co-founder of Genetic Networks, echoed this enthusiasm, stating, "Category V Biotech shares our dedication to leveraging genetics to revolutionize drug development. By joining forces, we envisage broadening the reach and impact of our platform, ultimately delivering superior medicines to patients in need."

Following the acquisition, Genetic Networks will operate as a wholly owned subsidiary of Category V Biotech, retaining its existing management team and facilities. Category V Biotech plans to leverage Genetic Networks' capabilities across its global Cannabis operations, including cultivation, biotech research, and retail.

This transaction is the culmination of years of discussions, awaiting the right moment for research and development in the United States to create pharmaceutical-grade products using Cannabis. With the recent announcement of the rescheduling of Cannabis from Controlled Substance I to Controlled Substance III, reflecting a change in U.S. policies, the long-awaited strategy can now come to fruition. This shift paves the way for Category V Biotech and Genetic Networks to capitalize on emerging opportunities in the Cannabis industry, driving innovation and advancing therapeutic solutions for patients.

Category V Biotech remains actively engaged in pursuing additional acquisitions in the Cannabis industry as part of its growth strategy, with further transactions expected to be announced in the coming months.

About Genetic Networks, LLC

Genetic Networks, LLC, established in 2015, has been at the forefront of serving three of the top ten bio-pharmaceutical companies with its GeneScape™ technology. GeneScape™ expedites drug asset development through applied molecular biology, offering a multidimensional map of diseases and drugs that integrates genome-wide functional assays of drug activity (H-Tech) and human genes and gene variants (Y-Tech) using proprietary analytics. Genetic Networks' GeneScape™ platform accelerates the discovery and development of optimal candidate compounds for pre-clinical and clinical testing, identifying the optimal intersection between targets and compounds in specific disease spaces through whole-genome genetic perturbation and analysis.

About Category V Biotech, LLC, Inc.

Category V Biotech, LLC, Inc. (OTC: CATV) aims to establish and operate a fully integrated global Cannabis company, encompassing biotech research, cultivation, manufacturing, and retail. Through strategic acquisitions and organic growth, the company strives to emerge as the world's leading provider of pharmaceutical Cannabis- based products and therapies.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements regarding Category V Biotech, LLC's business, which are not historical facts but are based on the company's current beliefs, expectations, and assumptions about its future business, plans, strategies, projections, anticipated events, and trends. Such forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are beyond the company's control. Actual results and financial conditions may differ materially from those indicated in the forward- looking statements due to various factors. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, made from time to time, except as required by law.

SOURCE: 4Cable TV International, Inc a/k/a Category V Biotech, LLC, Inc. (OTC: CATV)

Contact: info@4cabletvint.com, +1 3055289614

Cision View original content:https://www.prnewswire.com/news-releases/category-v-biotech-inc-announces-letter-of-intent-to-acquire-genetic-networks-expanding-into-biotechnology-sector-302146392.html

SOURCE 4Cable TV International, Inc.

$RENB News: Renovaro, Inc. Announces $10 million in Equity Committed

LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage.

“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO. “We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars.”

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.

$RENB News: Renovaro, Inc. Announces $10 million in Equity Committed

LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage.

“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO. “We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars.”

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.

Since the high sales and revenue surge for the latest IVDN fiscal quarter has already been reported in the company's official news on April 10th and May 30th, it is already a verified fact. As a fully reporting OTCQB listed equity, IVDN management is 100% accountable to the SEC for accuracy and truthfulness in everything they state in any public announcement. This includes press releases, the company website, Twitter (X) and the company filings. Real investors know this. Anonymous persons posting off-handed comments on chat boards have zero accountability to anyone and therefore zero credibility. Real investors know this too. There is plenty of verified and valuable information on the growing success of the IVDN business plan in the official news below.

Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html

Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html

World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640

LIG Assets, Inc. Announces Agreement With Insultex House Wrap
October 30, 2023
https://www.globenewswire.com/en/news-release/2023/10/30/2769422/0/en/LIG-Assets-Inc-Announces-Agreement-With-Insultex-House-Wrap.html

Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html

Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html

Innovative Designs, Inc. Receives $100,000 Direct Private Investment from Board Member Mr. Robert K. Adams
June 5, 2023
https://www.globenewswire.com/news-release/2023/06/05/2682134/0/en/Innovative-Designs-Inc-Receives-100-000-Direct-Private-Investment-from-Board-Member-Mr-Robert-K-Adams.html

Innovative Designs, Inc. Receives Significant New Orders for Its Unmatched Insultex House Wrap from Two Repeat Customers
June 1, 2023
https://www.globenewswire.com/news-release/2023/06/01/2680753/0/en/Innovative-Designs-Inc-Receives-Significant-New-Orders-for-Its-Unmatched-Insultex-House-Wrap-from-Two-Repeat-Customers.html

Innovative Designs Receives Patent for Propriety Process With Low Density Foam
April 20, 2023
https://www.globenewswire.com/news-release/2023/04/20/2651420/0/en/Innovative-Designs-Receives-Patent-for-Propriety-Process-With-Low-Density-Foam.html

$SHOT: Wellness And Dietary Supplement Company Safety Shot Reports Bringing World's First Patented Rapid Blood Alcohol Detox Solution To Market - Safety Shot (NASDAQ:SHOT) - Benzinga
Click here:
https://www.benzinga.com/partner/emerging-markets/24/06/39361121/wellness-and-dietary-supplement-company-safety-shot-reports-bringing-worlds-first-patent

$SHOT: Wellness And Dietary Supplement Company Safety Shot Reports Bringing World's First Patented Rapid Blood Alcohol Detox Solution To Market - Safety Shot (NASDAQ:SHOT) - Benzinga
Click here:
https://www.benzinga.com/partner/emerging-markets/24/06/39361121/wellness-and-dietary-supplement-company-safety-shot-reports-bringing-worlds-first-patent

$SHOT: Safety Shot Partners with Capital Drugs To Launch World's First Beverage To Reduce Blood Alcohol Content in 300 Pharmacies Across the Country

The First of its Kind Vitamin-Packed, Wellness Beverage Brand Continues to Amplify its In-Store Availability Nationwide

JUPITER, Fla., June 6, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company), announced today its partnership with Capital Drugs as the brand expands its nationwide availability. Making strides in connecting the brand to its overarching wellness purpose, Safety Shot will be available in all 300 of the drugstore chain's pharmacies across the United States.

Entering a key market for Safety Shot consumers, Capital Drugs is known for providing a wide range of pharmaceutical services and products tailored to specific health and wellness needs. Capital Drugs offers traditional pharmacy and clinical services in tandem with alternative medicine options such as supplements, vitamins, and homeopathic products.

"Entering Capital Drugs pharmacies is an integral next step in furthering Safety Shots key messaging and purpose of operating as a functional wellness beverage," said Josh Wagner, Chief Revenue Officer at Safety Shot. "Expanding on-shelf availability and having the product available for purchase in key locations like Capital Drug pharmacies is the brand's core mission, introducing the first-of-its-kind beverage to a like-minded consumer audience."

This latest affiliation aligns with the brand's comprehensive nationwide availability rollout and partnership expansion plan. This announcement comes on the heels of its Northeast expansion across New York and New Jersey through boutique broker Prime CBS and additional partnerships with GoPuff, BevMo and more.

About Safety Shot, Inc

Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.

SOURCE Safety Shot

$SHOT: Safety Shot Partners with Capital Drugs To Launch World's First Beverage To Reduce Blood Alcohol Content in 300 Pharmacies Across the Country

The First of its Kind Vitamin-Packed, Wellness Beverage Brand Continues to Amplify its In-Store Availability Nationwide

JUPITER, Fla., June 6, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company), announced today its partnership with Capital Drugs as the brand expands its nationwide availability. Making strides in connecting the brand to its overarching wellness purpose, Safety Shot will be available in all 300 of the drugstore chain's pharmacies across the United States.

Entering a key market for Safety Shot consumers, Capital Drugs is known for providing a wide range of pharmaceutical services and products tailored to specific health and wellness needs. Capital Drugs offers traditional pharmacy and clinical services in tandem with alternative medicine options such as supplements, vitamins, and homeopathic products.

"Entering Capital Drugs pharmacies is an integral next step in furthering Safety Shots key messaging and purpose of operating as a functional wellness beverage," said Josh Wagner, Chief Revenue Officer at Safety Shot. "Expanding on-shelf availability and having the product available for purchase in key locations like Capital Drug pharmacies is the brand's core mission, introducing the first-of-its-kind beverage to a like-minded consumer audience."

This latest affiliation aligns with the brand's comprehensive nationwide availability rollout and partnership expansion plan. This announcement comes on the heels of its Northeast expansion across New York and New Jersey through boutique broker Prime CBS and additional partnerships with GoPuff, BevMo and more.

About Safety Shot, Inc

Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.

SOURCE Safety Shot

$CYCA News: CyttaAIR Partners with FIZUAS to Dominate the American Drone Reseller and Advanced Streaming Technology Market

Massive Florida Demand for CyttaCOMMS and Drones Drives Partnership

LAS VEGAS, NV / ACCESSWIRE / June 13, 2024 / Cytta Corp (OTCQB:CYCA), a leading provider of innovative technology solutions for public safety and cybersecurity industries, is excited to announce that CyttaAIR, in an expansion of its longstanding reseller partnership with FIZUAS Unmanned Aircraft Systems, a premier national drone reseller, is now entering the drone reseller market. This strategic joint venture aims to meet the growing demand for American-made drones, particularly from law enforcement agencies transitioning away from foreign drones.

A Strategic Move in Response to Growing Demand

This expanded partnership with FIZUAS comes at a critical time when numerous law enforcement agencies in Florida are seeking guidance on which drone brands and models to purchase. This transition to American-made drones is driven by legislative changes and a heightened focus on data security. Through this joint venture, CyttaAIR will provide these agencies with top-tier, compliant drone options, enhancing their operational capabilities and ensuring adherence to new regulations.

Quote from Mike Elliott, VP of Business Development

"We are thrilled to be partnering with a premiere national drone reseller like FIZUAS," said Mike Elliott, VP of Business Development at Cytta Corp. "The number of law enforcement agencies in Florida asking about which drone brands and models to purchase has skyrocketed. This joint venture allows CyttaAIR to expand into this rapidly growing market, providing our clients with the best in American-made drone technology and our leading CyttaCOMMS secure video streaming solution."

Expanding CyttaAIR's Reach

This collaboration is poised to position CyttaAIR as a dominant player in the drone reseller market. By leveraging FIZUAS's extensive reseller network and expertise, CyttaAIR/FIZUAS will jointly offer a comprehensive range of drones equipped with the secure and collaborative capabilities of CyttaCOMMS. This move underscores Cytta Corp.'s commitment to providing cutting-edge technology solutions that meet the evolving needs of law enforcement and other critical sectors.

About Cytta Corp:

Cytta Corp. is a leading technology solutions provider dedicated to delivering innovative products and services across various industries and revolutionizes the integration, streaming, transfer, and storage of video and audio data. With a focus on safety, security, and efficiency, Cytta Corp strives to develop cutting-edge solutions that address real-world challenges in large markets.

The Company's proprietary CyttaCOMMS incident management system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.

About FIZUAS Unmanned Aircraft Systems

FIZUAS is a leading national drone reseller known for providing high-quality, reliable drone solutions to various industries. Their extensive network and extensive first responder and industry expertise make them a trusted partner for organizations looking to integrate drone technology into their operations.

Contact Information
Investor/Shareholder Contact:
Gary Zwetchkenbaum
PlumTree Consulting, LLC.
gzplumtree@gmail.com
Direct: (516)-455-7662

Cytta Corp.
Toll free #: 1 877 CYTTAUS (298 8287)
Call Local: 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com

Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com

Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708

SOURCE: Cytta Corp.

$CYCA News: CyttaAIR Partners with FIZUAS to Dominate the American Drone Reseller and Advanced Streaming Technology Market

Massive Florida Demand for CyttaCOMMS and Drones Drives Partnership

LAS VEGAS, NV / ACCESSWIRE / June 13, 2024 / Cytta Corp (OTCQB:CYCA), a leading provider of innovative technology solutions for public safety and cybersecurity industries, is excited to announce that CyttaAIR, in an expansion of its longstanding reseller partnership with FIZUAS Unmanned Aircraft Systems, a premier national drone reseller, is now entering the drone reseller market. This strategic joint venture aims to meet the growing demand for American-made drones, particularly from law enforcement agencies transitioning away from foreign drones.

A Strategic Move in Response to Growing Demand

This expanded partnership with FIZUAS comes at a critical time when numerous law enforcement agencies in Florida are seeking guidance on which drone brands and models to purchase. This transition to American-made drones is driven by legislative changes and a heightened focus on data security. Through this joint venture, CyttaAIR will provide these agencies with top-tier, compliant drone options, enhancing their operational capabilities and ensuring adherence to new regulations.

Quote from Mike Elliott, VP of Business Development

"We are thrilled to be partnering with a premiere national drone reseller like FIZUAS," said Mike Elliott, VP of Business Development at Cytta Corp. "The number of law enforcement agencies in Florida asking about which drone brands and models to purchase has skyrocketed. This joint venture allows CyttaAIR to expand into this rapidly growing market, providing our clients with the best in American-made drone technology and our leading CyttaCOMMS secure video streaming solution."

Expanding CyttaAIR's Reach

This collaboration is poised to position CyttaAIR as a dominant player in the drone reseller market. By leveraging FIZUAS's extensive reseller network and expertise, CyttaAIR/FIZUAS will jointly offer a comprehensive range of drones equipped with the secure and collaborative capabilities of CyttaCOMMS. This move underscores Cytta Corp.'s commitment to providing cutting-edge technology solutions that meet the evolving needs of law enforcement and other critical sectors.

About Cytta Corp:

Cytta Corp. is a leading technology solutions provider dedicated to delivering innovative products and services across various industries and revolutionizes the integration, streaming, transfer, and storage of video and audio data. With a focus on safety, security, and efficiency, Cytta Corp strives to develop cutting-edge solutions that address real-world challenges in large markets.

The Company's proprietary CyttaCOMMS incident management system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence. Their innovative new product, CyttaCARES , is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.

About FIZUAS Unmanned Aircraft Systems

FIZUAS is a leading national drone reseller known for providing high-quality, reliable drone solutions to various industries. Their extensive network and extensive first responder and industry expertise make them a trusted partner for organizations looking to integrate drone technology into their operations.

Contact Information
Investor/Shareholder Contact:
Gary Zwetchkenbaum
PlumTree Consulting, LLC.
gzplumtree@gmail.com
Direct: (516)-455-7662

Cytta Corp.
Toll free #: 1 877 CYTTAUS (298 8287)
Call Local: 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com

Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com

Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708

SOURCE: Cytta Corp.

$AVRW: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results

New Initiatives Showing Encouraging Results

SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.

Key financial highlights for the fourth quarter included the following:

Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.

Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.

Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.

Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.

Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.

"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.

Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.

Operational Highlights

Other operational highlights during the fourth quarter of 2023 included:

Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/

About Avenir Wellness Solutions, Inc.

Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.

About The Sera Labs, Inc.

Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.

Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.

CONTACTS:

Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com

$AVRW: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results

New Initiatives Showing Encouraging Results

SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.

Key financial highlights for the fourth quarter included the following:

Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.

Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.

Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.

Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.

Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.

"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.

Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.

Operational Highlights

Other operational highlights during the fourth quarter of 2023 included:

Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/

About Avenir Wellness Solutions, Inc.

Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.

About The Sera Labs, Inc.

Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.

Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.

CONTACTS:

Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com

$CCTG News: CCSC Technology International Holdings Limited Enters into Strategic Cooperation Framework Agreement with Innogetic International Limited

Hong Kong, June 13, 2024 (GLOBE NEWSWIRE) -- CCSC Technology International Holdings Limited (the “Company” or “CCSC”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced that on May 22, 2024, the Company entered into a strategic cooperation framework agreement (the “Agreement”) with Innogetic International Limited (“Innogetic”), a Hong Kong based company that engages in the following: industrial software development and system integration, automated equipment and smart assemble line development, and digital transformation services. This partnership aims to explore and apply digital technology such as artificial intelligence (“AI”) in the field of manufacturing by leveraging each company’s strength in technology research and manufacturing integrations.

Pursuant to the Agreement, CCSC and Innogetic agree to establish a joint venture in Hong Kong to carry out the cooperation. Both parties also agree to share information on AI technology trends and the application of typical industries such as manufacturing platforms and services.

Mr. Kung Lok Chiu, Chief Executive Officer and Director of the Company, commented, “We are thrilled to cooperate with Innogetic in the field of AI technology. This Agreement marks a significant milestone for both CCSC and Innogetic, setting the stage for groundbreaking advancements and growth in AI technology and its applications in the manufacturing sector. By sharing our resources and expertise, we aim to accelerate our transformation towards industrial digital intelligence. Going forward, we plan to continue driving innovation and efficiency, further enhancing our position in the manufacturing industry.”

About CCSC Technology International Holdings Limited

CCSC Technology International Holdings Limited, is a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products. The Company specializes in customized interconnect products, including connectors, cables and wire harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. The Company produces both OEM (“original equipment manufacturer”) and ODM (“original design manufacture”) interconnect products for manufacturing companies that produce end products, as well as electronic manufacturing services (“EMS”) companies that procure and assemble products on behalf of such manufacturing companies. The Company has a diversified global customer base located in more than 25 countries throughout Asia, Europe and the Americas. For more information, please visit the Company’s website: http://ir.ccsc-interconnect.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

CCSC Technology International Holdings Limited
Investor Relations Department
Email: ir@ccsc-interconnect.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

$CCTG News: CCSC Technology International Holdings Limited Enters into Strategic Cooperation Framework Agreement with Innogetic International Limited

Hong Kong, June 13, 2024 (GLOBE NEWSWIRE) -- CCSC Technology International Holdings Limited (the “Company” or “CCSC”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced that on May 22, 2024, the Company entered into a strategic cooperation framework agreement (the “Agreement”) with Innogetic International Limited (“Innogetic”), a Hong Kong based company that engages in the following: industrial software development and system integration, automated equipment and smart assemble line development, and digital transformation services. This partnership aims to explore and apply digital technology such as artificial intelligence (“AI”) in the field of manufacturing by leveraging each company’s strength in technology research and manufacturing integrations.

Pursuant to the Agreement, CCSC and Innogetic agree to establish a joint venture in Hong Kong to carry out the cooperation. Both parties also agree to share information on AI technology trends and the application of typical industries such as manufacturing platforms and services.

Mr. Kung Lok Chiu, Chief Executive Officer and Director of the Company, commented, “We are thrilled to cooperate with Innogetic in the field of AI technology. This Agreement marks a significant milestone for both CCSC and Innogetic, setting the stage for groundbreaking advancements and growth in AI technology and its applications in the manufacturing sector. By sharing our resources and expertise, we aim to accelerate our transformation towards industrial digital intelligence. Going forward, we plan to continue driving innovation and efficiency, further enhancing our position in the manufacturing industry.”

About CCSC Technology International Holdings Limited

CCSC Technology International Holdings Limited, is a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products. The Company specializes in customized interconnect products, including connectors, cables and wire harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. The Company produces both OEM (“original equipment manufacturer”) and ODM (“original design manufacture”) interconnect products for manufacturing companies that produce end products, as well as electronic manufacturing services (“EMS”) companies that procure and assemble products on behalf of such manufacturing companies. The Company has a diversified global customer base located in more than 25 countries throughout Asia, Europe and the Americas. For more information, please visit the Company’s website: http://ir.ccsc-interconnect.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

CCSC Technology International Holdings Limited
Investor Relations Department
Email: ir@ccsc-interconnect.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

$GTVH News: Golden Triangle Ventures Announces Launch of Its Freight Brokerage Division with Full Financial Support

LAS VEGAS, June 14, 2024 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC PINK: GTVH) (“GTV” or the “Company”) is excited to announce it has received financial commitment to launch an internal, full-service freight brokerage business which aims to significantly expand its logistics capabilities. This initiative follows the successful acquisition of Cargo Management Group from TK Zarro, LLC which included a logistics operation, brokerage business, licenses, and all associated assets. Management is working to complete the full transition of Cargo Management Group and its logistics brokerage operation that can provide an additional income stream with a strong growth potential.

The new freight brokerage business will leverage current infrastructure that was recently acquired along with extensive industry relationships of Cargo Management Group, which generated nearly $3 million in revenue for 2023. The recent acquisition includes a portfolio of contracts with industry leaders such as J.B. Hunt, C.H. Robinson, Coyote Logistics and Echo Global Logistics. These established partnerships will enable Cargo Management Group to provide comprehensive logistics solutions, including freight brokerage services, to its diverse clientele. After the full transition of the business is complete, Cargo Management Group looks forward to providing the unique ability to fully meet clients' needs with its assets and manage overflow through brokerage services.

To ensure a successful launch of its freight brokerage business, Cargo Management Group will establish a new location and call center to drive sales and manage operations efficiently. The Company received full financial support from TK Zarro to obtain state-of-the-art freight brokerage software, Transportation Management System (TMS), and load board subscriptions to streamline all operations and improve service delivery. Additionally, plans to hire and train skilled freight brokers, dispatchers, and customer service representatives are in motion to ensure a high level of expertise and efficiency in handling logistics operations. A comprehensive marketing strategy is being developed and will be implemented to attract new clients and build strong industry partnerships.

The freight brokerage industry, led by companies like Echo Global Logistics and Coyote Logistics, shows strong growth potential. Echo Global Logistics reported over $3 billion in revenue for 2023, while Coyote Logistics, a UPS company, continues to set high standards. GTV plans to follow these successful models, aiming to become a recognizable player in the industry, drive revenue growth and increase shareholder value. Industry leaders such as C.H. Robinson, J.B. Hunt, and Coyote Logistics have seen significant growth in share price and business expansion, a path GTV is preparing to follow.

About Cargo Management Group: http://www.CargoManagementGroup.com

About Golden Triangle Ventures, Inc.

Golden Triangle Ventures, Inc. or “GTV” is a multifaceted consulting Company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors, along with others that provide synergistic value to these three core divisions. The Company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The Company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors in which this Company aims to do business. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the Company. An amazing team of professionals support each division and continue to help the Company grow daily. Being a publicly traded Company gives the ability to provide the support needed to help each subsidiary grow into the business that management believes it can and will become.

Golden Triangle Ventures’ business model is supported by the drive for vertical integration to cut costs and maximize margins. Management strives to acquire entities and assets that they fully understand, which maintain the prospect for long-term exponential growth. The mission is to provide the necessary resources for each subsidiary to generate profit, and then allow them to leverage each other and maximize economic impact. In addition, GTV provides a professional corporate representation service to different companies in these sectors while consulting on a variety of different business development objectives.

The backbone of this business is truly a team of professional advisors looking to help companies with a multitude of corporate objectives. With an extensive Rolodex of relationships, management can help with a dynamic range of project obstacles while maintaining a quality service for each client the Company represents. No matter what the needs are, the team involved can help facilitate many different transactions successfully for all parties involved. The network of relationships expands to industry experts who can assist with project management, product sourcing, industrial agriculture project implementation and so much more. Golden Triangle Ventures develops strategies and detailed plans that are custom-tailored to each corporate need and objective in all areas of business.

The GTV business model is focused on the following core group of interests:

Acquisitions / Assets / Holdings - The Company currently owns a unique portfolio of companies that are all being developed and supported by GTV, each holding a common goal of making a positive impact in the industry in which they operate.

Services - Services are deployed through Golden Triangle Ventures to assist all the unique opportunities within its operation. The Company also offers its services to select opportunities that could develop synergistic value within the relationship between both companies through the result of its efforts.

Investments - Management identifies high-value opportunities and provides capital investments in several companies and projects being developed. Each investment is complemented by a hands-on approach of helping to develop the overall direction and strategic plan for each opportunity.

For more information, visit us at: http://www.GoldenTriangleInc.com

About Lavish Entertainment, Inc.

Lavish Entertainment, Inc. is a wholly owned subsidiary of Golden Triangle Ventures operating under its Entertainment Division. Currently conducting its business out of Las Vegas, Nevada, the Company started doing business in 2017 and was established with a vision of becoming nationally recognized in concert production. The Company currently has more than 30,000 national followers and nearly 100 team members who have helped Lavish successfully organize some of the most exciting electronic dance music concerts in Las Vegas. Lavish Entertainment strives to produce high-quality and professional events that provide an immersive experience through state-of-the-art production and sound implementation.

Lavish Entertainment is currently developing a flagship entertainment complex called Destino Ranch, which intends to become an ideal outdoor music and festival venue, immersive art installation, tourist attraction and world-renowned destination center. The Company recently secured a purchase agreement to acquire nearly 70 acres of prime and improved land for its Destino Ranch project, which is strategically located in Arizona. The property has upgrades that represent a substantial investment totaling nearly $6 million, which has turned this once vacant land into a beautiful oasis that provides the initial infrastructure needed to begin the development of Destino Ranch.

Lavish Entertainment has completed a full acquisition of ABI Create (or “ABI”), a premier event management and production firm, which is managing the development of its Destino Ranch project. Founded in 2015 by Marco Antonio Moreno (recently appointed as the new president and COO of Lavish Entertainment), ABI Create has delivered high-quality productions for a range of large-scale installations at major music festivals, sporting events and conventions across the United States. Notable projects include collaborations with the NFL Super Bowl, San Diego and New York Comic Con, EDC and Camp EDC, Bonnaroo Music Festival, the Waste Management Phoenix Open, Arnold Palmer Invitational, Burning Man, and many more.

Forward-Looking Statements

Certain information set forth in this press release contains "forward-looking information," including "future-oriented financial information" and "financial outlook," under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to give potential investors the opportunity to understand management's beliefs and opinions in respect to the future so they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material nonpublic information. In this regard, investors and others should note that we announce material financial information on our Company website, www.GoldenTriangleInc.com, in addition to SEC filings, press releases, public conference calls and webcasts. We also use social media to communicate with the public about our Company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, in light of the SEC's guidance, we encourage investors, the media and others interested in our Company to review the information we post on the following U.S. social media channels:

X: https://x.com/GTV_Inc

CONTACT INFORMATION:

Golden Triangle Ventures, Inc.

info@GoldenTriangleInc.com

Corporate Communications

IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year. This has been pre-announced in the last two IVDN news releases:

Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html

Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html

IVDN is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year. This has been pre-announced in the last two IVDN news releases:

Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html

Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html